CXCL9 and neoplasm: In such cases, therapeutic strategies that restore chemokine signaling (e.g., CXCL9/10-CXCR3 axis), enhance antigen presentation, or normalize tumor vasculature are essential to reinvigorate TIL activity within the TME (48, 169).